Pre-saturation of the liver and subsequent administration of the contrast agent
AssigneeB.Braun Melsungen AG
InventorsThore Dietrich, Riad Bourayou, Eckart Fleck, Thorsten Keller, Jürgen Schmitt, Doris Röthlein
Life of this patent
Estimating the term…
Abstract
The present invention relates to an aqueous formulation for use in diagnostic detection wherein the aqueous formulation is administered prior to the administration of a fluorinated contrast agent or composition comprising a fluorinated contrast agent as well as to a method of administration. The invention further relates to the use of said aqueous formulation for the diagnostic detection of inflammatory pathological conditions using MR imaging. In addition the invention relates to a kit as well as a diagnostic kit suitable for use in diagnostic detection.
Claims17
A method for diagnostic detection of pathological conditions, the method comprising:
- (a) parenterally administering a phagocytosable-component-containing oil-in-water emulsion to a patient, wherein the oil-in-water emulsion comprises an oil present in an amount ranging from 5 to 40 wt.-% based on the total weight of the oil-in-water emulsion, wherein the oil comprises a long chain triglyceride;
- (b) administering a composition comprising a fluorinated contrast agent and a medium chain triglyceride to the patient;
- and
- (c) acquiring one or more non-invasive images of the patient, wherein the one or more non-invasive images are acquired by a magnetic resonance imaging procedure.
A kit comprising
- a) a container comprising a phagocytosable-component-containing oil-in-water emulsion, wherein the phagocytosable-component-containing oil-in-water emulsion is a parenteral formulation, wherein the oil-in-water emulsion comprises an oil present in an amount ranging from 5 to 40 wt.-% based on the total weight of the oil-in-water emulsion, wherein the oil comprises a long chain triglyceride, and
- b) a container comprising a composition comprising a fluorinated contrast agent and a medium chain triglyceride, wherein the fluorinated contrast agent is selected from the group consisting of partially fluorinated carbon compounds, perfluorinated carbon compounds, linear, cyclic or polycyclic fluorinated alkanes, bis(perfluoroalkyl)alkenes, perfluoroethers, perfluoroamines, perfluoroalkyl bromide, and perfluoroalkyl chloride.
Dependencies are inferred from the claim text.